TABLE 2.

Treatment-Related Adverse Events (n = 19)

	Any Grade, No. (%)	Grade 3–5, No. (%)
Any	16 (84.2)	7 (36.8)
Serious	6 (31.6)	4 (21.1)
Led to discontinuation	0 (0.0)	0 (0.0)
Lead to death	0 (0.0)	0 (0.0)
>10% of patients
Fatigue	7 (36.8)	0 (0)
Rash, maculopapular	5 (26.3)	3 (15.8)
Nausea	4 (21.1)	1 (5.3)
Aspartate aminotransferase increased	4 (21.1)	0 (0)
Lipase increased	3 (15.8)	2 (10.5)
Alanine aminotransferase increased	3 (15.8)	0 (0)
Hypothyroidism	3 (15.8)	0 (0)
Pruritus	3 (15.8)	0 (0)
Vomiting	3 (15.8)	0 (0)
Anemia	2 (10.5)	1 (5.3)
Alkaline phosphatase increased	2 (10.5)	0 (0)
Chills	2 (10.5)	0 (0)
Pain	2 (10.5)	0 (0)
Immune-mediated	13 (68.4)	4 (21.1)
Rash, maculopapular	5 (26.3)	3 (15.8)
Aspartate aminotransferase increased	4 (21.1)	0 (0)
Lipase increased	3 (15.8)	2 (10.5)
Alanine aminotransferase increased	3 (15.8)	0 (0)
Hypothyroidism	3 (15.8)	0 (0)
Pruritus	3 (15.8)	0 (0)
Diarrhea	1 (5.3)	0 (0)
Hyperthyroidism	1 (5.3)	0 (0)
Infusion-related reaction	1 (5.3)	0 (0)
Serum amylase increased	1 (5.3)	0 (0)